Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies

Juntaro Matsuzaki, Hidekazu Suzuki, Toshihiro Nishizawa, Kenro Hirata, Hitoshi Tsugawa, Yoshimasa Saito, Sawako Okada, Seiichiro Fukuhara, Toshifumi Hibi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

Original languageEnglish
Pages (from-to)1643-1645
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number3
DOIs
Publication statusPublished - 2012 Mar

Fingerprint

Helicobacter pylori
Mutation
Clarithromycin
Metronidazole
Therapeutics
sitafloxacin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. / Matsuzaki, Juntaro; Suzuki, Hidekazu; Nishizawa, Toshihiro; Hirata, Kenro; Tsugawa, Hitoshi; Saito, Yoshimasa; Okada, Sawako; Fukuhara, Seiichiro; Hibi, Toshifumi.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 3, 03.2012, p. 1643-1645.

Research output: Contribution to journalArticle

@article{6dd363d8d10a4e0dab00bd04ddec94c5,
title = "Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies",
abstract = "Sitafloxacin-based triple therapy achieved 83.6{\%} (per-protocol) and 78.2{\%} (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.",
author = "Juntaro Matsuzaki and Hidekazu Suzuki and Toshihiro Nishizawa and Kenro Hirata and Hitoshi Tsugawa and Yoshimasa Saito and Sawako Okada and Seiichiro Fukuhara and Toshifumi Hibi",
year = "2012",
month = "3",
doi = "10.1128/AAC.05941-11",
language = "English",
volume = "56",
pages = "1643--1645",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies

AU - Matsuzaki, Juntaro

AU - Suzuki, Hidekazu

AU - Nishizawa, Toshihiro

AU - Hirata, Kenro

AU - Tsugawa, Hitoshi

AU - Saito, Yoshimasa

AU - Okada, Sawako

AU - Fukuhara, Seiichiro

AU - Hibi, Toshifumi

PY - 2012/3

Y1 - 2012/3

N2 - Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

AB - Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

UR - http://www.scopus.com/inward/record.url?scp=84863394554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863394554&partnerID=8YFLogxK

U2 - 10.1128/AAC.05941-11

DO - 10.1128/AAC.05941-11

M3 - Article

C2 - 22203601

AN - SCOPUS:84863394554

VL - 56

SP - 1643

EP - 1645

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -